SCHEMBL4800890

SCHEMBL4800890

c1ccc(CSc2nsc(OCc3ccoc3)n2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.49
SMN1; SMN2 Q16637 4/20 0.49
ALOX15 P16050 3/20 0.49
HSD17B10 Q99714 3/20 0.40
NPC1 O15118 3/20 0.37
NPSR1 Q6W5P4 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
MAPT P10636 3/20 0.36
HTT P42858 2/20 0.36
LMNA P02545 1/20 0.36
ALDH1A1 P00352 3/20 0.36
HPGD P15428 3/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
USP2 O75604 1/20 0.36
POLB P06746 1/20 0.36
THRB P10828 1/20 0.36
NR4A1 P22736 1/20 0.36
MAPK1 P28482 1/20 0.36
PTPN7 P35236 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5378195 0.87 RAB9A (0.59) RAB9ASMN1; SMN2ALOX15HSD17B10NPC1
SCHEMBL5388607 0.81 RAB9A (0.52) RAB9ASMN1; SMN2ALOX15HSD17B10NPC1
SCHEMBL4798924 0.81 MAPK1 (0.35) RAB9ASMN1; SMN2HSD17B10NPC1TDP1
SCHEMBL5372995 0.80 ALOX15 (0.51) RAB9ASMN1; SMN2ALOX15HSD17B10NPSR1
SCHEMBL5388491 0.78 CTSB (0.50) RAB9ASMN1; SMN2ALOX15NPC1TDP1
SCHEMBL5381470 0.75 RAB9A (0.48) RAB9ASMN1; SMN2ALOX15HSD17B10NPC1
SCHEMBL5422577 0.74 SMN1; SMN2 (0.42) RAB9ASMN1; SMN2ALOX15HSD17B10HTT
SCHEMBL14262178 0.73 SLC1A3 (0.35) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL13381950 0.73 SLC1A3 (0.35)
SCHEMBL4797641 0.72 RAB9A (0.66) RAB9ASMN1; SMN2ALOX15HSD17B10NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7342031-B2 Thiadiazole compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2008-03-11 US disclosed
US-7342031-B2 Thiadiazole compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2008-03-11 US disclosed
US-7342031-B2 Thiadiazole compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2008-03-11 US disclosed
US-20060014962-A1 Thiadiazole compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-01-19 US disclosed
EP-1550661-A1 THIADIAZOLE COMPOUND AND USE THEREOF Sumitomo Chemical Company, Limited (JP) 2005-07-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014962-A1 Thiadiazole compound and use thereof CBR3, TH, CYP2E1 RAB9A 1437/4885SMN1; SMN2 3070/4885ALOX15 537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.